2
Announcements
Trials
Browse
Landscape
Status
Recruiting
56
Active not recruiting
32
Not yet recruiting
12
Completed
11
Terminated
7
Withdrawn
3
Unknown
2
Enrolling by invitation
2
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
Afatinib
3
3-Iodobenzylguanidine
3
niraparib
2
lenvatinib
2
ibrutinib
2
gallium 68 PSMA-11
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Ramucirumab
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Gefitinib
2
Fluorouracil
2
Capecitabine
2
Amifampridine
2
Abiraterone Acetate
2
zenocutuzumab
1
vorasidenib
1
tucatinib
1
trilaciclib
1
trifluridine tipiracil drug combination
1
tovorafenib
1
talquetamab
1
tafasitamab
1
selpercatinib
1
sacituzumab govitecan
1
ripretinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
sacituzumab govitecan
×
Clear all
NCT04320693
2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing